Bio-Rad Laboratories logo

Bio-Rad LaboratoriesNYSE: BIO

Profile

Sector:

Healthcare

Country:

United States

IPO:

27 February 1980

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$10.31 B
-56%vs. 3y high
93%vs. sector
-vs. 3y high
-vs. sector
-26%vs. 3y high
49%vs. sector
-49%vs. 3y high
54%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:03:30 GMT
$368.42+$8.44(+2.34%)

Dividend

No data over the past 3 years
$649.73 M$681.29 M
$649.73 M$653.17 M

Analysts recommendations

Institutional Ownership

BIO Latest News

Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference
proactiveinvestors.com01 November 2024 Sentiment: POSITIVE

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will participate in the upcoming BIO-Europe 2024 conference in Stockholm. The event will allow Tiziana to engage with industry leaders, potential collaborators, and investors, emphasizing its recent clinical advancements, particularly data from its combination study involving Ozempic, a GLP-1 agonist.

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
globenewswire.com01 November 2024 Sentiment: POSITIVE

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference's partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent clinical progress, including data from its combination study involving Ozempic, a GLP-1 agonist.

BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket
zacks.com31 October 2024 Sentiment: POSITIVE

Bio-Rad witnesses growth across the Clinical Diagnostics segment in the third quarter, primarily driven by an increased demand for quality control and immunology products.

Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript
seekingalpha.com30 October 2024 Sentiment: POSITIVE

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Norman Schwartz - Chairman of the Board, President & Chief Executive Officer Jon DiVincenzo - President & Chief Operating Officer Roop Lakkaraju - Executive Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Leonard - UBS Brandon Couillard - Wells Fargo Jack Meehan - Nephron Research Tycho Peterson - Jefferies Operator Hello, everyone, and welcome to today's Bio-Rad Third Quarter 2024 Results Conference Call and Webcast. At this time to get started, all participants are in a listen-only mode.

BIO-TECHNE DECLARES DIVIDEND
prnewswire.com30 October 2024 Sentiment: POSITIVE

MINNEAPOLIS , Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2024. The quarterly dividend will be  payable November 22, 2024, to all common shareholders of record on November 11, 2024.

Tonix Pharmaceuticals to Present at BIO-Europe® 2024
globenewswire.com29 October 2024 Sentiment: POSITIVE

CHATHAM, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at BIO-Europe®, being held November 4-6, 2024, in Stockholm, Sweden. The presentation will take place on Monday, November 4, 2024, at 1:00 p.m. CET.

What to Expect From These 3 MedTech Stocks This Earnings Season
zacks.com29 October 2024 Sentiment: POSITIVE

Here is a sneak peek into how three MedTech companies, ZBH, BIO and TECH, are expected to fare in their upcoming quarterly results, slated to be released tomorrow.

FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
globenewswire.com28 October 2024 Sentiment: POSITIVE

HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that members of its senior leadership team will be presenting and be available for one-on-one meetings with investors at the following upcoming investor conferences.

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer
globenewswire.com21 October 2024 Sentiment: POSITIVE

SEATTLE, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) (“Atossa” or the “Company”), today announced that Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer, will join Per Hall, M.D., Professor of Epidemiology at the Department of Medical Epidemiology and Biostatistics at Karolinska Institute, at a fireside chat at BIO-Europe 2024. During the fireside chat, Drs. Quay and Hall will discuss a meaningful approach to combining a state-of-the-art, artificial intelligence (AI)-based risk model with promising emerging therapies that may help prevent breast cancer in high-risk patients. BIO-Europe 2024 is scheduled for November 4-6, 2024, in Stockholm, Sweden. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

BIO Gears Up for Q3 Earnings: Here's What You Need to Know
zacks.com17 October 2024 Sentiment: NEUTRAL

Within Bio-Rad's Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely affected sales.

What type of business is Bio-Rad Laboratories?

Bio-Rad Laboratories, Inc. produces and supplies products for scientific research, healthcare, analytical chemistry, and other markets with products and systems used for separating complex chemical and biological materials and identifying, analyzing, and purifying their components. Bio-Rad operates in six industry segments: scientific research, clinical diagnostics, food industry, spectroscopy, and bioengineering. The segments operate worldwide. Bio-Rad's clients include hospitals, major research institutions, biotechnology and pharmaceutical companies, as well as secondary and tertiary academic institutions. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

What sector is Bio-Rad Laboratories in?

Bio-Rad Laboratories is in the Healthcare sector

What industry is Bio-Rad Laboratories in?

Bio-Rad Laboratories is in the Medical Devices industry

What country is Bio-Rad Laboratories from?

Bio-Rad Laboratories is headquartered in United States

When did Bio-Rad Laboratories go public?

Bio-Rad Laboratories initial public offering (IPO) was on 27 February 1980

What is Bio-Rad Laboratories website?

https://www.bio-rad.com

Is Bio-Rad Laboratories in the S&P 500?

No, Bio-Rad Laboratories is not included in the S&P 500 index

Is Bio-Rad Laboratories in the NASDAQ 100?

No, Bio-Rad Laboratories is not included in the NASDAQ 100 index

Is Bio-Rad Laboratories in the Dow Jones?

No, Bio-Rad Laboratories is not included in the Dow Jones index

When was Bio-Rad Laboratories the previous earnings report?

No data

When does Bio-Rad Laboratories earnings report?

Next earnings report date is not announced yet